Modi Ventures

Lila Sciences is a technology company that specializes in accelerating scientific research. It develops artificial intelligence-driven tools and autonomous labs, focusing on life sciences, chemical sciences, and materials sciences. The platform aims to enhance research efficiency and facilitate scientific discoveries by processing vast amounts of data, designing experiments, generating hypotheses, and testing them in real-world environments. This enables scientists to achieve breakthroughs and innovate more rapidly.

Ignota Labs is a pioneering medical technology company focused on enhancing the drug discovery process through advanced artificial intelligence methods. By utilizing deep learning and machine learning algorithms, the company aims to analyze complex molecular data to predict toxicity early in the development of pharmaceuticals. This proactive approach helps to identify harmful compounds, thereby minimizing environmental impact and waste. Ignota Labs' innovative platform not only streamlines the drug discovery process but also enhances drug safety, ultimately facilitating the timely introduction of life-changing medications to the market.

Innotap is a prominent provider of energy trading and commodity trading software, specializing in real-time decision support applications for power traders. The company offers a suite of innovative tools, including DecisionDock, InstaTrend, RealDeal Dashboards, and PowerFeed for Excel, which facilitate the monitoring of market conditions and help traders make informed decisions. By leveraging cloud-based technology and aggregating data from Independent System Operators (ISOs) and Regional Transmission Organizations (RTOs), Innotap enables energy traders to respond swiftly to market changes and seize profitable opportunities. With a focus on enhancing decision-making processes, Innotap combines data visualization and analytics, presenting users with a rich graphical interface that streamlines access to real-time market data.

Lapsi Health is a medical technology company founded in January 2022 in Amsterdam that develops biomarker and sound‑based diagnostic solutions. The company creates advanced audio and photo‑sensor platforms that capture physiological data, which are then analyzed with artificial intelligence to provide non‑clinical, remote monitoring and screening for a range of diseases. By integrating a digital stethoscope with sophisticated sound processing and AI, Lapsi Health aims to democratize access to high‑quality healthcare insights, enabling patients and providers to detect and manage conditions outside traditional clinical settings.

General Proximity is a biotechnology company focused on proximity medicine, developing therapies that activate existing cellular machinery and advancing a new generation of induced-proximity medicines designed to treat harmful human diseases.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

PathPresenter is a global platform facilitating secure and compliant sharing of pathology images among professionals. Its mission is to enhance collaboration and patient care by connecting pathologists worldwide.

Latus Bio is a biotechnology company dedicated to developing innovative gene therapies for neurological diseases. It specializes in novel discovery approaches using non-human primate models, enabling precise delivery of therapeutic genes to targeted cells within the central nervous system. Latus Bio aims to enhance clinical safety and manufacturing efficiency by administering low doses of its proprietary adeno-associated virus (AAV) capsids.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Tiny Health is a prominent microbiome health platform focused on addressing chronic health conditions and optimizing overall well-being. The company offers innovative at-home microbiome testing kits, including the Gut Health Test specifically designed for pregnant mothers and their babies, as well as tests for older children and adults and Vaginal Health Tests. By utilizing shotgun metagenomics, Tiny Health provides families with personalized insights into their gut and vaginal microbiomes, allowing them to make informed dietary and lifestyle changes. To date, approximately 30,000 families have relied on Tiny Health's expertise to correct microbiome imbalances and enhance health outcomes, with many experiencing significant symptom reduction or even reversal of chronic conditions. The team at Tiny Health comprises leading scientists and medical professionals from prestigious institutions, ensuring a strong foundation in evidence-based health solutions.

Harbinger Health is a biotechnology company developing a two-tier testing model for early cancer detection using blood tests. It combines artificial intelligence with insights into the biology of early-stage cancer to identify cancer before it becomes visible or symptomatic, aiming to create low-cost, multi-cancer blood tests.

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, focused on drug discovery through innovative technology. Founded in 2016, the company specializes in designing and developing a platform that utilizes artificial intelligence and computational biology techniques to create macrocyclic peptides. These peptides target intracellular protein interactions, addressing drug targets that are typically considered undruggable. By harnessing machine learning to optimize chemical synthesis, Unnatural Products aims to accelerate the drug discovery process, offering potential therapeutic strategies for a wide range of medical conditions. Through its unique approach, the company seeks to pioneer new treatments where traditional methods have fallen short.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Atomic AI is a company focused on advancing drug discovery through the innovative integration of machine learning and structural biology, specifically targeting RNA. The firm operates a content intelligence platform that facilitates the rational design of new molecules and medicines using artificial intelligence. By leveraging engagement data from clients' analytics, Atomic AI gathers valuable insights and generates predictive reports regarding relevant topics, optimal publishing times, and effective distribution channels. This approach equips users with strategies to develop therapies aimed at treating or curing diseases through the manipulation of RNA structures.

Perceptive is a company focused on the design, development, and manufacturing of advanced medical devices specifically for the dentistry industry. It specializes in automated robotics technology that aims to revolutionize dental care by making image-guided robotic restorative dentistry a standard practice. The company's innovative technology enhances the precision of dental procedures, allowing dentists to more accurately identify and remove tooth decay, ultimately leading to superior restorations for patients. By improving the efficiency of dental care, Perceptive enables practitioners to deliver high-quality services at a lower cost and in a reduced timeframe, thereby increasing clinical capacity and advancing the standard of care in dentistry.

Flawless develops an AI-driven platform that enables perfect lip-syncing and translation of films into multiple languages. Its system preserves original performances, enhancing accessibility and potential audience for content.

Founded in 2015, Ashvattha Therapeutics develops precision therapeutics targeting actively endocytosing cells. Its pipeline focuses on neurology, oncology, and ophthalmology, aiming to treat diseases with improved efficacy and reduced side effects.

Lapsi Health is a medical technology company founded in January 2022 in Amsterdam that develops biomarker and sound‑based diagnostic solutions. The company creates advanced audio and photo‑sensor platforms that capture physiological data, which are then analyzed with artificial intelligence to provide non‑clinical, remote monitoring and screening for a range of diseases. By integrating a digital stethoscope with sophisticated sound processing and AI, Lapsi Health aims to democratize access to high‑quality healthcare insights, enabling patients and providers to detect and manage conditions outside traditional clinical settings.

Starling Medical is focused on creating a remote patient monitoring platform that facilitates at-home urine diagnostics, aiming to integrate seamlessly into everyday bathroom routines. The company designs healthcare devices that utilize mass spectroscopy-based sensors for continuous monitoring and early detection of health issues through urine analysis. By tracking changes in urine composition over time, Starling Medical's technology enables timely intervention for patients and healthcare providers, potentially preventing complications and reducing the need for hospitalizations. The organization is dedicated to developing predictive technology that enhances early detection of chronic health concerns, ultimately improving patient outcomes.